Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2020

View Archived Issues

SH-229: phase II data in combination with daclatasvir in Chinese patients with chronic HCV

Incyte initiates phase I study of INCB-099280 in solid tumors

Development of BI-1467335 discontinued for diabetic retinopathy

Phase III study evaluates NA-831 plus OPV as prevention and treatment of early onset of COVID-19

Dracen Pharmaceuticals begins first-in-human study of DRP-104

BeiGene starts phase I study of SARS-CoV-2 neutralizing antibody BGB-DXP-593

New candidate breast cancer risk gene identified

JNK as a novel therapeutic target in cholestatic liver diseases

CRISPR immune suppression strengthens CRISPR gene therapy

mTOR-targeting metabolite discovered

AKG for A-OK aging

GYS2 identified as potential new prognostic biomarker in HCC

QKI-7 targeting restores endothelial cell function and improves vascular complications in diabetes

New Nav1.8 channel blockers patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Adlai Nortye describes new PD-1/PD-L1 interaction inhibitors

Shenzhen Targetrx Biotechnology discovers RET inhibitors

An integrated pipeline for rapid discovery and validation of MAbs against viral pathogens

New PCSK9 inhibitors presented by the Wisconsin Alumni Research Foundation

Enterin identifies new PTP-1B inhibitors

Amplia receives ethics committee clearance for phase I trial of FAK inhibitor AMP-945

Inhibitory decoy gene created to inhibit Galpha-q for uveal melanoma treatment

Valneva advances chikungunya vaccine candidate VLA-1553 into phase III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...